News >

Midostaurin Recommended for EU Approval for AML

Jason Harris
Published: Friday, Jul 21, 2017

Bruno Strigini, CEO

Bruno Strigini, CEO
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of midostaurin (Rydapt) to treat adults with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation–positive.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication